drugset / Trial / NCT05131997

A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A

NCT05131997

Phase 3 Completed 290 enrolled Addpharma Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of AD-221 and AD-221A

Timeline

Start
2021-11-16
Primary completion
2022-06-08
Completion
2022-06-08

Drugs

EvaluationDrugModalityDoseRoute
Subject AD-221 Unknown
Subject AD-221A Unknown
Comparator Atorvastatin Small molecule
Comparator Ezetimibe Unknown

Indications